Changes

From McQuade et al. 2004 PMID 15582915

From McQuade et al. 2004 PMID 15582915

:Two treatment groups of six rats received either, lithium 3 mmol/kg/day or saline vehicle. Drug treatments were administered for 28 days as a constant infusion via subcutaneously placed  osmotic pumps (Alzet model 2ML4, DURECT Corporation, Cupertino, CA, USA) implanted under halothane anaesthesia. During drug treatment, in addition to tap water, all rats were given access to 0.9% saline to minimize any ionic chemical imbalances resulting from the diuretic properties of lithium. All rats weighed 160–180 g at the time of implantation. The dose of 0.75 meq/day was based on a predicted average weight of 250 g over the course of the 28-day treatment period  

:Two treatment groups of six rats received either, lithium 3 mmol/kg/day or saline vehicle. Drug treatments were administered for 28 days as a constant infusion via subcutaneously placed  osmotic pumps (Alzet model 2ML4, DURECT Corporation, Cupertino, CA, USA) implanted under halothane anaesthesia. During drug treatment, in addition to tap water, all rats were given access to 0.9% saline to minimize any ionic chemical imbalances resulting from the diuretic properties of lithium. All rats weighed 160–180 g at the time of implantation. The dose of 0.75 meq/day was based on a predicted average weight of 250 g over the course of the 28-day treatment period ... Mean plasma lithium levels after 28 days chronic lithium treatment were 0.50 ± 0.03 mmol / l.

From  Smith and Amdisen 1981 PMID 6121860

From  Smith and Amdisen 1981 PMID 6121860